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A Bayesian NMA using non-informative priors was conducted, based on linking 
trials with treatment and dose-specific common treatment arms. Assessment of 
model fit and selection of fixed versus random effects was based on the Deviance 
Information Criterion (DIC). Sensitivity analyses assessed the impact of individual 
trials and definition of priors. Consistency between direct and indirect evidence was 
assessed. Results: Ten studies reporting results at 26 weeks +/- 4 weeks were iden-
tified. HbA1c-reduction (D) for CANA 100mg was comparable to DPP-4s (D between 
0.05 and -0.14 versus sitagliptin and linagliptin respectively, with pairwise prob-
abilities (P) of being more effective between 33-88%), and higher for CANA 300mg, 
which was comparable to GLP-1s (D= 0.08;P= 31% and 0.01;P= 53%) versus liraglutide 
1.8mg and exenatide 10µg respectively) and biphasic insulin (D= 0.03;P= 43%). CANA 
300mg had the highest weight reduction with changes between 0.14kg;P= 93% (vs. 
exenatide 10µg) and 5.13kg;P= 100% (vs. biphasic insulin). The odds ratio for hypo-
glycaemia versus long-acting insulin were 0.31 and 0.39 for CANA 100mg and 300mg 
respectively, compared to 0.20-0.41 for other classes. ConClusions: NMA of add-
on therapies to MET+SU suggests that glycaemic reductions for CANA at 26 weeks 
are at least as large for CANA 100 mg and greater for CANA 300 mg compared to 
DPP-4s. CANA 300mg was found to be comparable to liraglutide 1.8mg and biphasic 
insulin. Weight reduction was similar to GLP-1s and substantially higher compared 
to all other classes. All classes showed significantly lower hypoglycaemic event 
rates compared to insulin.
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objeCtives: Liraglutide is an incretin-based (GLP-1 analog) therapy indicated 
for the treatment of patients with type 2 diabetes (T2DM). This study aimed to 
assess whether phase 3 clinical trial data, showing significantly greater reductions 
in HbA1c and body weight vs. the DPP-IV inhibitor sitagliptin is translated into 
routine clinical practice. Methods: This was a retrospective database analysis of 
the Clinical Practice Research Datalink (CPRD), a primary care database in the UK. 
Patients (≥ 18 years) diagnosed with T2DM and prescribed liraglutide or sitagliptin 
between July 2009 and July 2012, were included. Patients on insulin or fixed dose 
metformin combinations at therapy initiation were excluded. Outcomes included: 
% of patients achieving ≥ 1% HbA1c reduction; % of patients with HbA1c reduction 
≥ 1% and weight reduction ≥ 3% (NICE criteria); % of patients achieving treatment 
target HbA1c < 7%; absolute change in HbA1c, weight (BMI), systolic blood pres-
sure and blood lipids. Results: Baseline demographics: 294 liraglutide and 2790 
sitagliptin patients with a mean age of 55.7 (SD 10.6) and 62 (SD 11.0) years and 
36.4% and 40.5% female respectively. Patients had a baseline HbA1c of 8.9% (SD 
1.9) and 8.6% (SD 1.5), a baseline BMI of 39.3 (SD 7.1) and 33.3 (SD 6.4) and had been 
diagnosed with diabetes 7.1 and 7.2 years prior to start of current treatment for 
liraglutide and sitagliptin respectively. Comparative effectiveness analysis dem-
onstrated superior reductions for liraglutide vs. sitagliptin in HbA1c (%) (-0.89 
vs. -0.57, p< .01), weight (Kg) (-3.78 vs. -1.12, p< .0001), BMI (-1.3 vs. -0.4, p< .0001) 
and systolic blood pressure (mmHg) (-4.1 vs. -0.37, p< .0005) after 6 months of 
therapy. No statistically significant differences were observed in total cholesterol 
and HDL reductions. ConClusions: The superior control and weight reduction of 
liraglutide vs. sitagliptin observed in clinical trials is reflected in routine primary 
care clinical practice.
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objeCtives: Anti-depressant use could complicate the weight change effect of 
anti-diabetes (AD) medications. This study examined if different newly prescribed 
AD medications were associated with weight loss in a 12-months period in type 
II diabetes (T2D) patients who were on anti-depressants. Methods: The study 
included patients who were on anti-depressants (selective serotonin reuptake 
inhibitors, SSRI, or tricyclic antidepressants,TCA) and prescribed a new AD dur-
ing 1995-2011 from the UK Clinical Practice Research Datalink (CPRD.) Patients on 
more than one ADs are included if ADs are within same weight-change category, 
categorized as weight-gain agents (WG)(sulfonylureas (SU), thiazolidinediones 
(TZD)) and weight- neutral/ loss agents (WN/L)(metformin(MET), DPP-4 inhibitors 
(DPP-4), GLP-1 agonists (GLP-1). Descriptive analyses and multivariate regression 
examined the association between weight loss ≥ 3% and newly prescribed AD medi-
cations grouped by weight change category. Results: This study included 3,445 
T2D patients, of whom 2,041 were SSRI users and 1,404 were TCA users. Mean (sd) 
age was 60(±13.2) years for SSRI users and 64(±12.0) years for TCA users. Baseline 
mean (sd) weight was 92.86(±22.24) kg for SSRI users and 89.31(±19.86) kg for TCA 
users. At 12 months after initiation of AD therapy, with baseline age, weight, and 
other characteristics controlled, the likelihood of achieving weight loss of ≥ 3% was 
higher for those prescribed a WN/L agents versus those prescribed a WG agents 
regardless of the anti-depressant medicine currently used: For SSRI users OR= 2.84; 
95% CI [1.89, 4.32]; for TCA users OR = 1.51; 95% CI [1.03, 2.23]. ConClusions: T2D 
anti-depressant users prescribed WN/L agents had higher odds of actual weight loss 
of ≥ 3%, compared to those prescribed WG agents. This association holds regardless 
of the anti-depressant medicine patients are currently taking. For T2D patients on 
anti-depressants, considering different weight change effects when initiating anti-
diabetes therapy is needed.
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objeCtives: Chemotherapy with docetaxel was the first therapy approved for 
the treatment of metastatic Castrate-Resistant Prostate Cancer (mCRPC) while 
others came along rather recently. With all the treatment options available now, 
current treatment strategies to appropriately sequence these agents are not known. 
This study aims to describe mCRPC current treatment paradigms, with specific 
attention to docetaxel, in Scotland. Methods: A retrospective chart review was 
conducted. A panel of Scottish physicians was contacted to identify patients diag-
nosed with mCRPC between 2008 and 2013. Collected data included demographics, 
disease history, sequencing of therapies (type, duration and time-to-event), reason 
for switch or discontinuation, drug-related serious adverse events and hospitali-
sations. Descriptive analyses were performed. Time-to-event was analysed using 
the Kaplan-Meier method. Results: Twelve physicians in Scotland completed the 
survey and 34 patients were included in the analysis. Mean age at mCRPC diagnosis 
was 62 years (range 56-69 years). The mean duration between mCRPC diagnosis and 
the date of last contact was 1.20 years. Postcastration, most patients (19/34, 56%), 
received docetaxel as first-line. The second most frequent first-line was bicaluta-
mide (14/34, 41%), alone (9/14, 64%) or in combination with LHRHa. Abiraterone was 
frequently prescribed as next (second or third) line of therapy after docetaxel (6/21, 
29%). The median time to switch was 105 days (range 20-235 days) and did not differ 
between patients with docetaxel versus other as first-line (p = 0.17). Most patients 
switched after radiographic progression or PSA rise. Serious adverse events and hos-
pitalisations were rarely reported. ConClusions: These findings provide insights 
into the treatment pathway of mCRPC patients in Scotland. Chemotherapy with 
docetaxel and hormonal agents appear to be the most utilised therapies. Switch 
from first-line treatment occurred in approximately 3.5 months and was facilitated 
by radiographic progression or PSA rise. A larger retrospective chart review is needed 
to confirm these results.
DiaBetes/enDoCrine DisorDers – Clinical outcomes studies
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objeCtives: There has been a rising concern about the association between incre-
tin enhancers and acute pancreatitis (AP). Previous research showed conflicting 
findings, and this analysis of the FDA Adverse Event Reporting System (FAERS) 
aims at investigating signals of AP across pharmacological classes of anti-diabe-
tes medications (ADM) and within incretin enhancers class. Methods: Adverse 
event reports submitted to FAERS between 1997Q3-2012Q1 were analyzed. The out-
come was defined by MedDRA Preferred Term (PT) “pancreatitis acute”; exposures 
were defined by generic names of ADM. Sensitivity analyses were conducted by 
creating a custom term (CT) for outcome: “autoimmune pancreatitis”, “ischemic 
pancreatitis”, “pancreatitis”, “pancreatitis acute”, “pancreatitis hemorrhagic”, and 
“pancreatitis necrotizing”. Reports of other pancreatic disorders were excluded. 
Disproportionality analysis by proportional reporting ratio (PRR) and 95% confi-
dence interval (LL05-UL95) is applied to detect AP signals compared to all ADM. 
Associations with LL05≥ 2 are significant signals. Results: A total of1183 AP 
PT and 4481 CT reports for ADM were identified (incretin enhancers, n= 912 and 
n= 3,704, respectively). Corresponding PRR and (LL05-UL95) were: metformin 0.98 
(0.83-1.16) and 0.52 (0.47-0.59); sulfonylureas 0.53 (0.37-0.75) and 0.35 (0.28-0.43); 
thiazolidinediones 0.12 (0.09-0.16) and 0.12 (0.10-0.14); meglitinides 0.54 (0.31-0.93) 
and 0.39 (0.28-0.54); incretin enhancers 1.94 (1.87-2.00) and 2.09 (2.06-2.12); and 
combinations 0.65 (0.47-0.88) and 0.81 (0.70-0.93). Compared to all ADM, estimates 
for incretin enhancers were: exenatide 1.46 (1.37-1.55) and 1.54 (1.49-1.59); liraglutide 
4.90 (4.37-5.48) and 4.00 (2.73-4.28); saxagliptin 4.47 (3.00-6.67) and 4.60 (3.73-5.67); 
and sitagliptin 2.33 (1.95-2.78) and 4.02 (3.75-4.31). There were no reports of AP PT 
for linagliptin, but 39 reports of CT with estimates of 6.41 (4.64-8.85) were identi-
fied. ConClusions: Compared to other ADM, incretin enhancers are associated 
with higher than expected reporting of AP. Prescribers should monitor patients 
with diabetes for signs and symptoms of pancreatitis while treated with incretin 
enhancers. Given limitations of spontaneous reporting systems, pharmacoepide-
miological studies are required to test the generated hypothesis and to draw clini-
cally rigorous conclusions.
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objeCtives: To assess the relative efficacy and safety of canagliflozin (CANA), a 
sodium-glucose co-transporter inhibitor, as an add-on to MET+SU, versus DPP-4 
inhibitors, GLP-1 agonists and insulin, using Bayesian network meta-analysis 
(NMA). Methods: A systematic literature review was conducted according to 
NICE guidelines. Outcomes of interest included HbA1c, weight and hypoglycaemia. 
